Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes

Journal of Steroid Biochemistry and Molecular Biology

Volumn 122, Issue 1-3, 2010, Pages 21-27

  Gathercole, Laura L ^a   Stewart, Paul M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

11 Hydroxysteroid dehydrogenase; Diabetes; Glucocorticoids; Obesity

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 3 CHLORO 2 METHYL N [4 [2 (4 METHYL 1 PIPERAZINYL) 2 OXOETHYL] 2 THIAZOLYL]BENZENESULFONAMIDE; CORTISONE; ENZYME INHIBITOR; GLUCOCORTICOID; HYDROCORTISONE; INCB 013739; PF 91575; UNCLASSIFIED DRUG; CARBENOXOLONE;

ANIMAL MODEL; CUSHING SYNDROME; DIABETES MELLITUS; ENZYME INHIBITION; HORMONE METABOLISM; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; CARBENOXOLONE; DIABETES MELLITUS; ENZYME INHIBITORS; HUMANS; HYDROCORTISONE; OBESITY;

RODENTIA;

EID: 77956489883     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2010.03.060     Document Type: Review

References (98)

1. Brunani A., Palli D., Salvini S., Masala G., Vallone L., Barantani E., et al. Short- and long-term mortality in a prevalent cohort of morbidly obese patients in Italy. Eur. J. Nutr. 2002, 41(4):183-185.
2. Kahn S.E. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003, 46(1):3-19.
3. De Ferranti S.D., Osganian S.K. Epidemiology of paediatric metabolic syndrome and type 2 diabetes mellitus. Diab. Vasc. Dis. Res. 2007, 4(4):285-296.
4. Friedman T.C., Mastorakos G., Newman T.D., Mullen N.M., Horton E.G., Costello R., et al. Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM. Endocr. J. 1996, 43(6):645-655.
5. Wang Z., Frederick J., Garabedian M.J. Deciphering the phosphorylation " code" of the glucocorticoid receptor in vivo. J. Biol. Chem. 2002, 277(29):26573-26580.
6. Mason S.A., Housley P.R. Site-directed mutagenesis of the phosphorylation sites in the mouse glucocorticoid receptor. J. Biol. Chem. 1993, 268(29):21501-21504.
7. Le Drean Y., Mincheneau N., Le Goff P., Michel D. Potentiation of glucocorticoid receptor transcriptional activity by sumoylation. Endocrinology 2002, 143(9):3482-3489.
8. Murphy P.J., Morishima Y., Kovacs J.J., Yao T.P., Pratt W.B. Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone. J. Biol. Chem. 2005, 280(40):33792-33799.
9. Morishima Y., Kanelakis K.C., Murphy P.J., Lowe E.R., Jenkins G.J., Osawa Y., et al. The hsp90 cochaperone p23 is the limiting component of the multiprotein hsp90/hsp70-based chaperone system in vivo where it acts to stabilize the client protein:hsp90 complex. J. Biol. Chem. 2003, 278(49):48754-48763.
10. Pratt W.B., Toft D.O. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr. Rev. 1997, 18(3):306-360.
11. Medh R.D., Webb M.S., Miller A.L., Johnson B.H., Fofanov Y., Li T., et al. Gene expression profile of human lymphoid CEM cells sensitive and resistant to glucocorticoid-evoked apoptosis. Genomics 2003, 81(6):543-555.
12. Barnes P.J., Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 1997, 336(15):1066-1071.
13. Hafezi-Moghadam A., Simoncini T., Yang Z., Limbourg F.P., Plumier J.C., Rebsamen M.C., et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat. Med. 2002, 8(5):473-479.
14. Taskinen M.R., Nikkila E.A., Pelkonen R., Sane T. Plasma lipoproteins, lipolytic enzymes, and very low density lipoprotein triglyceride turnover in Cushing's syndrome. J. Clin. Endocrinol. Metab. 1983, 57(3):619-626.
15. Dolinsky V.W., Douglas D.N., Lehner R., Vance D.E. Regulation of the enzymes of hepatic microsomal triacylglycerol lipolysis and re-esterification by the glucocorticoid dexamethasone. Biochem. J. 2004, 378(Pt 3):967-974.
16. Morgan S.A., Sherlock M., Gathercole L.L., Lavery G.G., Lenaghan C., Bujalska I.J., et al. 11{beta}-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes 2009.
17. Nechushtan H., Benvenisty N., Brandeis R., Reshef L. Glucocorticoids control phosphoenolpyruvate carboxykinase gene expression in a tissue specific manner. Nucleic Acids Res. 1987, 15(16):6405-6417.
18. Adams C.M. Role of the transcription factor ATF4 in the anabolic actions of insulin and the anti-anabolic actions of glucocorticoids. J. Biol. Chem. 2007, 282(23):16744-16753.
19. Gregoire F., Genart C., Hauser N., Remacle C. Glucocorticoids induce a drastic inhibition of proliferation and stimulate differentiation of adult rat fat cell precursors. Exp. Cell Res. 1991, 196(2):270-278.
20. Hauner H., Schmid P., Pfeiffer E.F. Glucocorticoids and insulin promote the differentiation of human adipocyte precursor cells into fat cells. J. Clin. Endocrinol. Metab. 1987, 64(4):832-835.
21. Bader T., Zoumakis E., Friedberg M., Hiroi N., Chrousos G.P., Hochberg Z. Human adipose tissue under in vitro inhibition of 11beta-hydroxysteroid dehydrogenase type 1: differentiation and metabolism changes. Horm. Metab. Res. 2002, 34(11-12):752-757.
22. Buren J., Liu H.X., Jensen J., Eriksson J.W. Dexamethasone impairs insulin signalling and glucose transport by depletion of insulin receptor substrate-1, phosphatidylinositol 3-kinase and protein kinase B in primary cultured rat adipocytes. Eur. J. Endocrinol. 2002, 146(3):419-429.
23. Lundgren M., Buren J., Ruge T., Myrnas T., Eriksson J.W. Glucocorticoids down-regulate glucose uptake capacity and insulin-signaling proteins in omental but not subcutaneous human adipocytes. J. Clin. Endocrinol. Metab. 2004, 89(6):2989-2997.
24. Sakoda H., Ogihara T., Anai M., Funaki M., Inukai K., Katagiri H., et al. Dexamethasone-induced insulin resistance in 3T3-L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduction. Diabetes 2000, 49(10):1700-1708.
25. Turnbow M.A., Keller S.R., Rice K.M., Garner C.W. Dexamethasone down-regulation of insulin receptor substrate-1 in 3T3-L1 adipocytes. J. Biol. Chem. 1994, 269(4):2516-2520.
26. Gathercole L.L., Bujalska I.J., Stewart P.M., Tomlinson J.W. Glucocorticoid modulation of insulin signaling in human subcutaneous adipose tissue. J. Clin. Endocrinol. Metab. 2007, 92(11):4332-4339.
27. Wang Y., Jones V.B., Urs S., Kim S., Soltani-Bejnood M., Quigley N., et al. The human fatty acid synthase gene and de novo lipogenesis are coordinately regulated in human adipose tissue. J. Nutr. 2004, 134(5):1032-1038.
28. Ashby P., Robinson D.S. Effects of insulin, glucocorticoids and adrenaline on the activity of rat adipose-tissue lipoprotein lipids. Biochem. J. 1980, 188(1):185-192.
29. Fried S.K., Russell C.D., Grauso N.L., Brolin R.E. Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissues of obese women and men. J. Clin. Invest. 1993, 92(5):2191-2198.
30. Ottosson M., Vikman-Adolfsson K., Enerback S., Olivecrona G., Bjorntorp P. The effects of cortisol on the regulation of lipoprotein lipase activity in human adipose tissue. J. Clin. Endocrinol. Metab. 1994, 79(3):820-825.
31. Slavin B.G., Ong J.M., Kern P.A. Hormonal regulation of hormone-sensitive lipase activity and mRNA levels in isolated rat adipocytes. J. Lipid Res. 1994, 35(9):1535-1541.
32. Villena J.A., Roy S., Sarkadi-Nagy E., Kim K.H., Sul H.S. Desnutrin, an adipocyte gene encoding a novel patatin domain-containing protein, is induced by fasting and glucocorticoids: ectopic expression of desnutrin increases triglyceride hydrolysis. J. Biol. Chem. 2004, 279(45):47066-47075.
33. Olswang Y., Blum B., Cassuto H., Cohen H., Biberman Y., Hanson R.W., et al. Glucocorticoids repress transcription of phosphoenolpyruvate carboxykinase (GTP) gene in adipocytes by inhibiting its C/EBP-mediated activation. J. Biol. Chem. 2003, 278(15):12929-12936.
34. Delaunay F., Khan A., Cintra A., Davani B., Ling Z.C., Andersson A., et al. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J. Clin. Invest. 1997, 100(8):2094-2098.
35. Ohneda M., Johnson J.H., Inman L.R., Unger R.H. GLUT-2 function in glucose-unresponsive beta cells of dexamethasone-induced diabetes in rats. J. Clin. Invest. 1993, 92(4):1950-1956.
36. Lambillotte C., Gilon P., Henquin J.C. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J. Clin. Invest. 1997, 99(3):414-423.
37. Marin P., Andersson B., Ottosson M., Olbe L., Chowdhury B., Kvist H., et al. The morphology and metabolism of intraabdominal adipose tissue in men. Metabolism 1992, 41(11):1242-1248.
38. Fraser R., Ingram M.C., Anderson N.H., Morrison C., Davies E., Connell J.M. Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 1999, 33(6):1364-1368.
39. Lottenberg S.A., Giannella-Neto D., Derendorf H., Rocha M., Bosco A., Carvalho S.V., et al. Effect of fat distribution on the pharmacokinetics of cortisol in obesity. Int. J. Clin. Pharmacol. Ther. 1998, 36(9):501-505.
40. Pasquali R., Biscotti D., Spinucci G., Vicennati V., Genazzani A.D., Sgarbi L., et al. Pulsatile secretion of ACTH and cortisol in premenopausal women: effect of obesity and body fat distribution. Clin. Endocrinol. (Oxf.) 1998, 48(5):603-612.
41. Ljung T., Andersson B., Bengtsson B.A., Bjorntorp P., Marin P. Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: a dose-response study. Obes. Res. 1996, 4(3):277-282.
42. Marin P., Darin N., Amemiya T., Andersson B., Jern S., Bjorntorp P. Cortisol secretion in relation to body fat distribution in obese premenopausal women. Metabolism 1992, 41(8):882-886.
43. Whorwood C.B., Mason J.I., Ricketts M.L., Howie A.J., Stewart P.M. Detection of human 11beta-hydroxysteroid dehydrogenase isoforms using reverse-transcriptase-polymerase chain reaction and localization of the type 2 isoform to renal collecting ducts. Mol. Cell. Endocrinol. 1995, 110(1-2):R7-R12.
44. Whorwood C.B., Ricketts M.L., Stewart P.M. Epithelial cell localization of type 2 11beta-hydroxysteroid dehydrogenase in rat and human colon. Endocrinology 1994, 135(6):2533-2541.
45. Arriza J.L., Weinberger C., Cerelli G., Glaser T.M., Handelin B.L., Housman D.E., et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987, 237(4812):268-275.
46. Edwards C.R., Stewart P.M., Burt D., Brett L., McIntyre M.A., Sutanto W.S., et al. Localisation of 11beta-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 1988, 2(8618):986-989.
47. Palermo M., Shackleton C.H., Mantero F., Stewart P.M. Urinary free cortisone and the assessment of 11beta-hydroxysteroid dehydrogenase activity in man. Clin. Endocrinol. (Oxf.) 1996, 45(5):605-611.
48. Stewart P.M., Krozowski Z.S., Gupta A., Milford D.V., Howie A.J., Sheppard M.C., et al. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11beta-hydroxysteroid dehydrogenase type 2 gene. Lancet 1996, 347(8994):88-91.
49. Ricketts M.L., Shoesmith K.J., Hewison M., Strain A., Eggo M.C., Stewart P.M. Regulation of 11beta-hydroxysteroid dehydrogenase type 1 in primary cultures of rat and human hepatocytes. J. Endocrinol. 1998, 156(1):159-168.
50. Jamieson P.M., Chapman K.E., Edwards C.R., Seckl J.R. 11Beta-hydroxysteroid dehydrogenase is an exclusive 11beta-reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology 1995, 136(11):4754-4761.
51. Bujalska I.J., Walker E.A., Hewison M., Stewart P.M. A switch in dehydrogenase to reductase activity of 11beta-hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells. J. Clin. Endocrinol. Metab. 2002, 87(3):1205-1210.
52. Stewart P.M., Murry B.A., Mason J.I. Human kidney 11beta-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform. J. Clin. Endocrinol. Metab. 1994, 79(2):480-484.
53. Bujalska I.J., Walker E.A., Tomlinson J.W., Hewison M., Stewart P.M. 11Beta-hydroxysteroid dehydrogenase type 1 in differentiating omental human preadipocytes: from de-activation to generation of cortisol. Endocr. Res. 2002, 28(4):449-461.
54. Ozols J. Lumenal orientation and post-translational modifications of the liver microsomal 11beta-hydroxysteroid dehydrogenase. J. Biol. Chem. 1995, 270(17):10360.
55. Bujalska I.J., Draper N., Michailidou Z., Tomlinson J.W., White P.C., Chapman K.E., et al. Hexose-6-phosphate dehydrogenase confers oxo-reductase activity upon 11beta-hydroxysteroid dehydrogenase type 1. J. Mol. Endocrinol. 2005, 34(3):675-684.
56. Bujalska I.J., Hewitt K.N., Hauton D., Lavery G.G., Tomlinson J.W., Walker E.A., et al. Lack of hexose-6-phosphate dehydrogenase impairs lipid mobilization from mouse adipose tissue. Endocrinology 2008, 149(5):2584-2591.
57. Lavery G.G., Walker E.A., Draper N., Jeyasuria P., Marcos J., Shackleton C.H., et al. Hexose-6-phosphate dehydrogenase knock-out mice lack 11beta-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation. J. Biol. Chem. 2006, 281(10):6546-6551.
58. Morton N.M., Paterson J.M., Masuzaki H., Holmes M.C., Staels B., Fievet C., et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004, 53(4):931-938.
59. Ehehalt R., Fullekrug J., Pohl J., Ring A., Herrmann T., Stremmel W. Translocation of long chain fatty acids across the plasma membrane-lipid rafts and fatty acid transport proteins. Mol. Cell. Biochem. 2006, 284(1-2):135-140.
60. Kotelevtsev Y., Holmes M.C., Burchell A., Houston P.M., Schmoll D., Jamieson P., et al. 11Beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. U.S.A. 1997, 94(26):14924-14929.
61. Masuzaki H., Paterson J., Shinyama H., Morton N.M., Mullins J.J., Seckl J.R., et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001, 294(5549):2166-2170.
62. Masuzaki H., Yamamoto H., Kenyon C.J., Elmquist J.K., Morton N.M., Paterson J.M., et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J. Clin. Invest. 2003, 112(1):83-90.
63. Kershaw E.E., Morton N.M., Dhillon H., Ramage L., Seckl J.R., Flier J.S. Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 2005, 54(4):1023-1031.
64. Paterson J.M., Morton N.M., Fievet C., Kenyon C.J., Holmes M.C., Staels B., et al. Metabolic syndrome without obesity: hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(18):7088-7093.
65. Stewart P.M., Boulton A., Kumar S., Clark P.M., Shackleton C.H. Cortisol metabolism in human obesity: impaired cortisone→cortisol conversion in subjects with central adiposity. J. Clin. Endocrinol. Metab. 1999, 84(3):1022-1027.
66. Valsamakis G., Anwar A., Tomlinson J.W., Shackleton C.H., McTernan P.G., Chetty R., et al. 11Beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2004, 89(9):4755-4761.
67. Lindsay R.S., Wake D.J., Nair S., Bunt J., Livingstone D.E., Permana P.A., et al. Subcutaneous adipose 11beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J. Clin. Endocrinol. Metab. 2003, 88(6):2738-2744.
68. Kannisto K., Pietilainen K.H., Ehrenborg E., Rissanen A., Kaprio J., Hamsten A., et al. Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J. Clin. Endocrinol. Metab. 2004, 89(9):4414-4421.
69. Goedecke J.H., Wake D.J., Levitt N.S., Lambert E.V., Collins M.R., Morton N.M., et al. Glucocorticoid metabolism within superficial subcutaneous rather than visceral adipose tissue is associated with features of the metabolic syndrome in South African women. Clin. Endocrinol. (Oxf.) 2006, 65(1):81-87.
70. Engeli S., Bohnke J., Feldpausch M., Gorzelniak K., Heintze U., Janke J., et al. Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes. Res. 2004, 12(1):9-17.
71. Paulmyer-Lacroix O., Boullu S., Oliver C., Alessi M.C., Grino M. Expression of the mRNA coding for 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J. Clin. Endocrinol. Metab. 2002, 87(6):2701-2705.
72. Rask E., Olsson T., Soderberg S., Andrew R., Livingstone D.E., Johnson O., et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J. Clin. Endocrinol. Metab. 2001, 86(3):1418-1421.
73. Rask E., Walker B.R., Soderberg S., Livingstone D.E., Eliasson M., Johnson O., et al. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity. J. Clin. Endocrinol. Metab. 2002, 87(7):3330-3336.
74. Sandeep T.C., Andrew R., Homer N.Z., Andrews R.C., Smith K., Walker B.R. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 2005, 54(3):872-879.
75. Desbriere R., Vuaroqueaux V., Achard V., Boullu-Ciocca S., Labuhn M., Dutour A., et al. 11Beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring) 2006, 14(5):794-798.
76. Michailidou Z., Jensen M.D., Dumesic D.A., Chapman K.E., Seckl J.R., Walker B.R., et al. Omental 11beta-hydroxysteroid dehydrogenase 1 correlates with fat cell size independently of obesity. Obesity (Silver Spring) 2007, 15(5):1155-1163.
77. Paulsen S.K., Pedersen S.B., Fisker S., Richelsen B. 11Beta-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization. Obesity (Silver Spring) 2007, 15(8):1954-1960.
78. Veilleux A., Rheaume C., Daris M., Luu-The V., Tchernof A. Omental adipose tissue 11{beta}-HSD1 oxoreductase activity, body fat distribution and metabolic alterations in women. J. Clin. Endocrinol. Metab. 2009, 94(9):3550-3557.
79. Baudrand R., Carvajal C.A., Riquelme A., Morales M., Solis N., Pizarro M., et al. Overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in hepatic and visceral adipose tissue is associated with metabolic disorders in morbidly obese patients. Obes. Surg. 2010, 20(1):77-83.
80. Tomlinson J.W., Sinha B., Bujalska I., Hewison M., Stewart P.M. Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J. Clin. Endocrinol. Metab. 2002, 87(12):5630-5635.
81. Abdallah B.M., Beck-Nielsen H., Gaster M. Increased expression of 11beta-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes. Eur. J. Clin. Invest. 2005, 35(10):627-634.
82. Barf T., Vallgarda J., Emond R., Haggstrom C., Kurz G., Nygren A., et al. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1. J. Med. Chem. 2002, 45(18):3813-3815.
83. Alberts P., Engblom L., Edling N., Forsgren M., Klingstrom G., Larsson C., et al. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002, 45(11):1528-1532.
84. Alberts P., Nilsson C., Selen G., Engblom L.O., Edling N.H., Norling S., et al. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 2003, 144(11):4755-4762.
85. Sundbom M., Kaiser C., Bjorkstrand E., Castro V.M., Larsson C., Selen G., et al. Inhibition of 11betaHSD1 with the S-phenylethylaminothiazolone BVT116429 increases adiponectin concentrations and improves glucose homeostasis in diabetic KKAy mice. BMC Pharmacol. 2008, 8:3.
86. Hermanowski-Vosatka A., Balkovec J.M., Cheng K., Chen H.Y., Hernandez M., Koo G.C., et al. 11Beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J. Exp. Med. 2005, 202(4):517-527.
87. Lloyd D.J., Helmering J., Cordover D., Bowsman M., Chen M., Hale C., et al. Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis. Diabetes Obes. Metab. 2009, 11(7):688-699.
88. Berthiaume M., Laplante M., Festuccia W.T., Cianflone K., Turcotte L.P., Joanisse D.R., et al. 11Beta-HSD1 inhibition improves triglyceridemia through reduced liver VLDL secretion and partitions lipids toward oxidative tissues. Am. J. Physiol. Endocrinol. Metab. 2007, 293(4):E1045-E1052.
89. Berthiaume M., Laplante M., Festuccia W., Gelinas Y., Poulin S., Lalonde J., et al. Depot-specific modulation of rat intraabdominal adipose tissue lipid metabolism by pharmacological inhibition of 11beta-hydroxysteroid dehydrogenase type 1. Endocrinology 2007, 148(5):2391-2397.
90. Berthiaume M., Laplante M., Festuccia W.T., Berger J.P., Thieringer R., Deshaies Y. Additive action of 11beta-HSD1 inhibition and PPAR-gamma agonism on hepatic steatosis and triglyceridemia in diet-induced obese rats. Int. J. Obes. (Lond.) 2009, 33(5):601-604.
91. Zhang X., Zhou Z., Yang H., Chen J., Feng Y., Du L., et al. 4-(Phenylsulfonamidomethyl)benzamides as potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1 with efficacy in diabetic ob/ob mice. Bioorg. Med. Chem. Lett. 2009, 19(15):4455-4458.
92. Walker B.R., Connacher A.A., Lindsay R.M., Webb D.J., Edwards C.R. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J. Clin. Endocrinol. Metab. 1995, 80(11):3155-3159.
93. Andrews R.C., Rooyackers O., Walker B.R. Effects of the 11beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J. Clin. Endocrinol. Metab. 2003, 88(1):285-291.
94. Tomlinson J.W., Sherlock M., Hughes B., Hughes S.V., Kilvington F., Bartlett W., et al. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. J. Clin. Endocrinol. Metab. 2007, 92(3):857-864.
95. Bhat B.G., Hosea N., Fanjul A., Herrera J., Chapman J., Thalacker F., et al. Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11-hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 2008, 324(1):299-305.
96. Courtney R., Stewart P.M., Toh M., Ndongo M.N., Calle R.A., Hirshberg B. Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor. J. Clin. Endocrinol. Metab. 2008, 93(2):550-556.
97. incyte, 2008. http://incyte.com/index.html.
98. Rosenstock J., Banarer S., Fonseca V., Inzucchi S., Hollis G., Flores R., et al. Efficacy and safety of the 11-beta-HSD1 inhibitor, INCB13739, added to Metformin therapy in patients with Type 2 diabetes. Proceedings of the 69th Scientific Sessions Meeting of the American Diabetes Association 2009, LB3.